Novartis AG (VTX:NOVN) has been assigned a CHF 80 price objective by investment analysts at Goldman Sachs Group, Inc. (The) in a note issued to investors on Friday. The brokerage currently has a “neutral” rating on the stock.
NOVN has been the subject of a number of other reports. Morgan Stanley set a CHF 75 price target on shares of Novartis AG and gave the company a “sell” rating in a research report on Monday, May 29th. J P Morgan Chase & Co set a CHF 70 price target on shares of Novartis AG and gave the company a “neutral” rating in a research report on Saturday, May 20th. Deutsche Bank AG set a CHF 80 price target on shares of Novartis AG and gave the company a “neutral” rating in a research report on Friday, July 7th. HSBC Holdings plc set a CHF 85 price target on shares of Novartis AG and gave the company a “buy” rating in a research report on Wednesday, June 21st. Finally, Berenberg Bank set a CHF 85 price target on shares of Novartis AG and gave the company a “neutral” rating in a research report on Friday. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of CHF 82.30.
Novartis AG (VTX NOVN) opened at 80.15 on Friday. The company has a 50-day moving average price of CHK 79.68 and a 200-day moving average price of CHK 75.84. Novartis AG has a 12-month low of CHK 67.40 and a 12-month high of CHK 84.35.
WARNING: “Novartis AG (NOVN) PT Set at CHF 80 by Goldman Sachs Group, Inc. (The)” was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/2724546/novartis-ag-novn-pt-set-at-chf-80-by-goldman-sachs-group-inc-the.html.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.